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Abstract
Tumor cell dissemination in cancer patients is associated with a significant reduction in their survival and quality of life.
The ubiquitination pathway plays a fundamental role in the maintenance of protein homeostasis both in normal and
stressed conditions and its dysregulation has been associated with malignant transformation and invasive potential of
tumor cells, thus highlighting its value as a potential therapeutic target. In order to identify novel molecular targets of
tumor cell migration and invasion we performed a genetic screen with an shRNA library against ubiquitination
pathway-related genes. To this end, we set up a protocol to specifically enrich positive migration regulator candidates.
We identified the deubiquitinase USP19 and demonstrated that its silencing reduces the migratory and invasive
potential of highly invasive breast cancer cell lines. We extended our investigation in vivo and confirmed that mice
injected with USP19 depleted cells display increased tumor-free survival, as well as a delay in the onset of the tumor
formation and a significant reduction in the appearance of metastatic foci, indicating that tumor cell invasion and
dissemination is impaired. In contrast, overexpression of USP19 increased cell invasiveness both in vitro and in vivo,
further validating our findings. More importantly, we demonstrated that USP19 catalytic activity is important for the
control of tumor cell migration and invasion, and that its molecular mechanism of action involves LRP6, a Wnt co-
receptor. Finally, we showed that USP19 overexpression is a surrogate prognostic marker of distant relapse in patients
with early breast cancer. Altogether, these findings demonstrate that USP19 might represent a novel therapeutic
target in breast cancer.
Introduction
Cell migration plays a crucial role in a wide variety of
physiological processes1. Its activation is highly regulated
both spatially and temporarily, contributing to the main-
tenance of tissue and cellular homeostasis1,2. Therefore, it
is not surprising that when deregulated, migration is
associated with the development and progress of multiple
pathologies, including cancer2–4.
Alteration or exacerbation of malignant tumor cell
migration and dissemination is the principal cause of
death due to solid tumors5.
In addition, it was observed that decreasing the migra-
tory capabilities of tumor cells can restore and increase
the susceptibility to chemotherapeutic treatments6,7.
Consequently, targeting genes that regulate cell motility
could be beneficial in the treatment of highly aggressive
cancers8–10.
Cell motility is a complex process that requires post-
translational regulation of a wide variety of proteins.
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Ubiquitination is an important form of protein post-
translational modification that consists in the conjugation
of ubiquitin polypeptides to target proteins11,12, and is
responsible for regulating different processes13,14. The
reversion or modification of poly-ubiquitin chains is car-
ried out by deubiquitinating enzymes (DUBs)15.
To identify novel molecular targets within the ubiquiti-
nation pathway that positively regulate migration we
conducted a loss-of-function genetic screen using an epi-
thelial cell line derived from human triple-negative breast
cancer (MDAMB231) infected with a pooled shRNA
interference library. This type of cancer is associated with
aggressive behavior and an overall poor prognosis16.
From our screen, we identified the Ubiquitin-specific
protease 19 (USP19) as a candidate gene associated with
the regulation of cell migration. USP19 presents different
isoforms, some of them have a cytoplasmic localization
while others have a transmembrane domain that serves as
anchorage to the endoplasmic reticulum17,18. This DUB is
associated with protein quality control and cellular
homeostasis17–21. In particular, it has been demonstrated
that USP19 regulates LRP6 stability, a co-receptor of the
Wnt signaling cascade22. Aberrant activation of this
pathway and LRP6 polymorphisms and overexpression
have been associated with susceptibility to the develop-
ment of different cancers, including breast cancer23–27.
To validate USP19 function as a positive regulator of
migration and invasion, we performed a series of in vitro
and in vivo experiments analyzing USP19’s role in colo-
nization and tumor formation. In addition, we showed
that USP19 overexpression is associated with distant
relapse in patients diagnosed with early breast cancer.
Collectively, our data suggest that USP19 plays a crucial
role in breast cancer cell dissemination, and we provide
novel evidence that it can be a prognostic marker and
attractive candidate for the development of new ther-
apeutic strategies.
Materials and methods
Cell lines and cell culture
Cell lines were obtained from the ATCC and cultured in
Dulbecco’s modified Eagle’s medium (DMEM) (Gibco)
supplemented with 10% fetal bovine serum (FBS) (Nato-
cor, Córdoba, Argentina), 50 U/ml penicillin-streptomy-
cin, and 200 μM L-glutamine at 37 °C and 5% CO2 in a
humidified incubator. ATCC uses morphology, kar-
yotyping, and PCR-based approaches to confirm the
identity of human cell lines. Mycoplasm contamination
was evaluated monthly by PCR, and cell lines were cul-
tured less than three months.
shRNA screening and plasmid transfections
A pool of plasmids encoding 1885 shRNAs targeting
407 different genes related to the ubiquitination pathway
in the pLKO.1 backbone produced by The RNAi Con-
sortium (TRC, Sigma-Aldrich, St. Louis, MO) were
obtained from the University of Colorado.
For single shRNA transduction, TRCN51715 and
TRCN51716 (USP19 shRNA# 1 and 2, respectively),
TRCN33406, and TRCN33408 (LRP6 shRNA# 1 and 2,
respectively), and SHC001 PLKO.1 vectors were used.
For overexpression experiments, transfections were
performed using Lipofectamine 2000 reagent (Invitrogen,
Carlsbad, CA). GFP-tagged wild type and catalytically
dead mutant (C506S) USP19 plasmids were a gift of Dr.
Urbé (University of Liverpool, UK), and GFP-tagged ΔTM
USP19 plasmid was obtained by generating a premature
stop by mutagenesis PCR from wild-type USP19 vector.
Transwell migration assay
After starvation for 24 h (0.1% FBS), 5 × 104 cells were
added to the top chamber of 24-well transwells (BD
Bioscience, Bedford, MA, Cat#353097), and 10% FBS
assay medium was added to the bottom chambers and
incubated for 24 h. After non-migratory cell removal,
membranes were fixed, stained with 4′,6-diamidino-2-
phenylindole and imaged using a Zeiss Axio Observer Z1
Inverted Epi-fluorescence microscope.
For the screen, 6.6 × 105 starved MDAMB231 cells were
plated onto 6-well transwell chambers (BD Bioscience,
Bedford, MA, Cat# 353093). After a 24-hour incubation,
the non-migratory cells were collected, propagated, and
allowed to re-migrate for enrichment purposes. Cells from
8 transwells were combined per cycle to ensure a >700
library coverage. Simultaneously, migration in each cycle
was determined in 24-well plates as described before.
Quantitative PCR
Total RNA was extracted using TRIzol reagent (Invi-
trogen, Thermo Fisher Scientific) and cDNA synthesis
was carried out using M-MLV reverse transcriptase in the
presence of RNasin RNase-inhibitor (Promega) and an
oligo(dT) primer (Invitrogen).
Quantitative real-time PCR was carried out using the
FastStart Essential DNA Green Master kit (Roche) at an
annealing temperature of 60 °C for 35 cycles, and a CFX96
PCR Detection System (Biorad). Expression was calcu-
lated by the comparative CT (ΔCT) method with GAPDH
for normalization.
Western blot analysis
Cells were lysed in lysis buffer (50 mM Tris-HCl pH 7.4,
250mM NaCl, 25 mM NaF, 2 mM EDTA, 0.1% Triton-X,
with protease inhibitors mix (Complete ULTRA, Roche),
1 mM 1,4-DTT, 1 μM NaOV, 10 nM okadeic acid), and
protein concentrations were determined using the BCA
assay Kit (Pierce). Equal amounts of protein were sepa-
rated by 8–12% SDS-PAGE and transferred to PVDF
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membranes (Millipore-Merck). Membranes were incu-
bated with primary antibodies: rabbit anti-USP19 (Bethyl
Cat#A301-587A), mouse anti-tubulin and mouse anti-
GFP (Santa Cruz Biotechnology, Cat#sc-398103, and
Cat#sc-9996 B2, respectively), mouse anti-β-actin and
rabbit anti-LRP6 (Cell Signaling, Cat#3700 and Cat#2560
C5C7, respectively) and HRP-conjugated secondary anti-
bodies: anti-rabbit and anti-mouse (GE Healthcare
Cat#NA934 and Cat#NA931, respectively), and then
detected using an ECL SuperSignal West Femto and West
Pico detection kit (Pierce).
Wound-healing assays
Confluent monolayers were starved for 24 h (0.1% FBS)
and a single scratch was created using a micropipette tip.
Cells were washed and incubated with 3% FBS medium at
37 °C to enable migration.
Agar invasion assay
The procedure was performed as previously28–30 with
minor modifications, included in the Supplementary
Materials.
Noble agar assay
This experiment was performed as previously31 with
minor modifications, described in the Supplementary
Materials.
Matrigel three-dimensional cell culture
Experiments were carried out based on experimental
settings described before32–35. A detailed description is
included in the Supplementary Materials.
Mouse tumorigenesis and metastasis models
NOD SCID mice were originally purchased from Jack-
son Laboratories (Bar Harbor, ME, USA), and bred in
IBioBA’s animal facility under a pathogen-free environ-
ment. For all experiments, 7/8-week-old mice were used
in accordance with protocols approved by the Institu-
tional Board on Animal Research and Care Committee
(CICUAL, Experimental Protocol #63, 22.nov.2016),
School of Exact and Natural Sciences, University of
Buenos Aires. 4 weeks after birth, mice from each sex
were randomly divided at a density no more than 5 ani-
mals/cage. At the time of injection, cages for the different
treatments were arbitrary selected. Sample size was cal-
culated using G*Power (version 3.1.9.6; Heinrich Heine
University Düsseldorf, Germany). The following design
specifications were taken into account: α= 0.05; (1-ß)=
0.8; effect size ƒ= 0.4.
For in vivo mouse tumor studies, 5 × 105 cells in 100 μl
of PBS were subcutaneously injected in the mammary fat
pads of female mice. Tumors were measured every 3 days
and tumor volumes were calculated using the formula:
Volume=½ (width2 × length). Area Under Curve analysis
was performed using measurements from mice alive at
the end of the experiment.
For the experimental metastasis assay, 1 × 106 cells in
200 μl of PBS were injected in the lateral tail vein of male
mice. Lungs were harvested 60 days post-injection, fixed
in buffered formalin and then stored in 70% ethanol until
use for DNA quantification (as described before ref. 36) or
paraffin embedding, or insufflated with a 15% India Ink
solution and counterstained with Fekete’s solution for
macrometastasis exposure and imaging.
In silico analysis of USP19 mRNA expression among the
TCGA-BRCA dataset
Pre-processed USP19 expression levels among 800 pri-
mary breast carcinomas with intrinsic subtype data and
their integrated pathway activities (pathway activity - z
score of 1387 constituent PARADIGM pathways) were
obtained from the TCGA Breast Cancer (BRCA) dataset
at UCSC Xena browser (http://xena.ucsc.edu/). The
PARADIGM algorithm integrates pathway, expression,
and copy number data to infer activation of pathway
features within a superimposed pathway network struc-
ture extracted from NCI-PID, BioCarta, and Reactome37.
Briefly, Luminal A/B primary breast cancer group
(n= 600) was divided into low (n= 77) or high (n= 209)
USP19 expression levels according to the StepMiner one-
step algorithm (http://genedesk.ucsd.edu/home/public/
StepMiner/). These two groups were then compared at
their integrated pathway activities to identify the most
relevant signaling pathways associated with USP19
expression using the SAM test (p < 0.01; Fold Change >
1.5) with MultiExperiment Viewer Software (MeV 4.9).
Patients immunohistochemistry
Patients inclusion criteria are described in the Supple-
mentary Materials. Tissue microarrays (TMA) were con-
structed by punching 2-mm-diameter cores from invasive
breast carcinoma areas, as previously described38. TMA
sections were incubated overnight with the rabbit anti-
USP19 polyclonal antibody (LifeSpan, Cat#LS-C353286)
or the anti-E-cadherin mouse monoclonal antibody (clone
HECD-1, Zymed Laboratories Inc., San Francisco, CA),
after applying the MW antigen retrieval technique at
750W for 10min in 10mM Sodium Citrate Buffer
(pH 6.0).
The immunohistochemical analysis was carried out by
two pathologists (R.L., S.B.) by agreement, with both
blinded to the clinicopathological information. USP19
expression in patients’ samples was reported as the per-
cent of cells with positive cytoplasmatic staining, and
dichotomized (high vs. low, Supp. Fig. 1) according to the
ROC analysis. The optimal cut-off parameter for USP19
positive expression was 50%. E-cadherin positivity was
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defined as a membrane-associated, linear pattern of
immunoreactivity which decorated the cell membrane
entirely.
The immunohistochemical results for the estrogen
receptor (ER), progesterone receptor (PR), Ki67, and
HER2 status were obtained from the patient hospital
records.
Disease-free survival (DFS) was defined as the interval
from surgery to the first of the following events: tumor
relapse at local or distant sites. Distant relapse-free sur-
vival (DRFS) was defined as the time from surgery to the
occurrence of distant relapse.
Statistical analysis
Results are presented as Box-and-whisker plots with
median interquartile ranges plus minimum to max-
imum. n indicates the number of independent repli-
cates. The one-way ANOVA with Dunnett’s multiple-
comparison test as well as non-parametric Kruskal–
Wallis and Dunn’s Tests were used to compare treat-
ments to their corresponding control, and adjusted p-
values are indicated. P-value differences of <0.05 were
considered statistically significant. GraphPad Prism and
SPSS (version 15.0, Chicago, IL) statistical software
were used.
Pearson’s χ2 or Fisher’s exact tests were used to assess
the relations between the tumor USP19 protein expres-
sion and the patient clinicopathological parameters. The
Log-Rank (Mantel-Cox) test was used to analyze differ-
ences between the survival curves, and Cox’s proportional
hazard model was used to evaluate the association of
USP19 expression with survival time, using covariates
(tumor size, grade, and ER, PR, Ki-67, HER2, and
USP19 status).
Results
Migration-based screen to identify ubiquitination-pathway
genes with novel regulatory functions
In order to identify novel positive regulators of cell
migration within the ubiquitination pathway, we per-
formed an shRNA-based functional selection screen
(Fig. 1A). A pooled recombinant lentiviral shRNA library
targeting over 400 human ubiquitination-related genes
was stably transduced into breast cancer cells. The func-
tional selection consisted in placing the mixed population
into the upper compartment of a transwell unit and
allowing migration through the perforated membrane to
the lower compartment. Cells that exhibited reduced
migration were isolated and amplified. We performed
subsequent enrichment cycles until cells lost about 80% of
their initial migratory potential (Fig. 1B). After every
enrichment cycle, we evaluated shRNAs relative abun-
dance in the cell population by PCR amplification and
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Fig. 1 shRNA-based selection of positive regulators of cell
migration. A Overview of the selection procedure. The production
and infection of a ubiquitination-related lentiviral shRNA library are
described in Methods. Two weeks after lentiviral infection and
selection, MDAMB231 cells were seeded onto transwell inserts and
allowed to migrate across the porous membrane for 24 h in order to
select cells with a decreased migration phenotype. Migrating cells
were removed and non-migrating cells were collected from the
inserts upper compartment and amplified. Cells were then reseeded
onto transwell culture inserts for a subsequent cycle of selection; this
procedure was repeated until cells lost 80% of their initial migratory
potential. After every cycle of selection, the relative abundance of the
different shRNAs was evaluated using Next-Generation Sequencing.
B Transwell assay was used every other enrichment cycle to determine
the percentage of migratory cells and monitor the selection process.
C shRNAs’ abundance was estimated after each selection cycle.
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Fig. 1C, as enrichment cycles increased, we observed a
marked reduction in the number of shRNAs, suggesting
that the selection process was efficient. As a control, we
used an empty vector-transduced cell line.
Selection of candidate genes
After the selection process, we followed an analytical
workflow to select candidate genes for further validation











































































































































































Fig. 2 (See legend on next page.)
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effects, we discarded those genes for which only one
shRNA targeting its sequence was found in the sequen-
cing results. These criteria allowed us to identify 30 genes
whose depletion altered migration. Half of these genes
had already been associated with migration, invasion,
metastasis or tumorigenesis, and served as a proof of
principle for the efficacy and specificity of our screen
(Supp. Fig. 2 and Supp. Table 1). Among the identified
candidates, we focused our attention on the study of the
deubiquitinase USP19.
Validation of USP19 as a regulator of cell migration
In order to validate USP19 as a potential regulator of
cell migration, we established stable MDAMB231 cell
lines transduced individually with two different shRNAs
targeting USP19 expression (named shRNA#1 and
shRNA#2). Our results showed that both caused a sig-
nificant reduction in USP19 mRNA and protein levels
(Fig. 2B).
It is conceivable that shRNAs promoting cell pro-
liferation may have also been enriched during the func-
tional selection, as they provide cells an advantage during
the in vitro amplification step. To discard this possibility,
we performed proliferation curves of control and USP19-
silenced cell lines. We observed no differences between
the different cell lines doubling rates (Fig. 2C, Supp. Fig.
3), providing evidence for a direct role of USP19 in the
control of cell migration.
Next, we used transwell migration and wound-healing
assays to confirm the effect of USP19 depletion on cell
motility. As shown in Fig. 2D and E, USP19 knockdown
significantly decreased the migratory potential of cells
relative to the control cell line. More detailed analysis on
the wound-healing assay indicated that wound-edge cells
speed and total displacement were significantly reduced in
USP19 knockdown cells, and they presented a minor
increase in persistence relative to control cells (Supp. Fig. 4).
We also compared the effect on migration of
USP19 silencing with USP10 silencing, one of the already
published candidate genes obtained from our screen39–41.
Our results indicate that knock down of both genes
impair migration to a similar extent (Supp. Fig. 5).
Altogether, these experiments indicate that
USP19 silencing affects cell migration in vitro. We further
confirmed our findings using another highly invasive
breast cancer cell line (Supp. Fig. 6).
USP19 knockdown impairs invasion
Cell motility is often associated with increased tumor
cell invasion and is a characteristic trait of aggressive
tumor cells42,43. Therefore, we decided to investigate the
effect of USP19 depletion on tumor cell invasion.
To this end, we first analyzed the ability of cells to
invade agar spots. Our results show that USP19 knock-
down significantly reduced the number of invading cells
as well as their total displacement, compared to the
control cell line (Fig. 3A).
We next performed a 3D growth assay by seeding cells
at low confluence into noble agar, an anchorage-
independent matrix. After 6 weeks in culture, the con-
trol cell line formed bigger colonies compared to USP19-
silenced cell lines (Fig. 3B), indicating that colonization,
matrix invasion and anchorage-independent growth in
these conditions is partially impaired in cells where
USP19 expression is reduced.
Finally, we assessed growth and invasion into a
reconstituted extracellular matrix that provides ancho-
rage (Matrigel®). Cell lines expressing USP19 shRNAs
showed colonies with a significantly smaller size than
the control cell line (Fig. 3C), indicating that USP19 is
required for an efficient invasion even when an ancho-
rage is provided.
We further validated our results using another breast
cancer cell line (Supp. Fig. 6).
Collectively, our results indicate that USP19 knockdown
inhibits tumor cell invasion in vitro.
(see figure on previous page)
Fig. 2 Validation and characterization of USP19 as a regulator of cell migration. A Workflow used to select a candidate regulatory gene.
MDAMB231 cells were stably transduced with control empty vector shRNA (control) or two different shRNAs (#1 & #2) targeting USP19. B Efficiencies
of shRNA-mediated knockdown were confirmed by RT-PCR (top, n= 5, one-way ANOVA, Dunnett’s multiple comparison test. shRNA#1 p= 0.0329
and shRNA#2 p= 0.0013) and Western Blotting (middle and bottom, n= 4, one-way ANOVA, Dunnett’s multiple comparison test. shRNA#1 p=
0.0227 and shRNA#2 p= 0.0006). (C) Crystal violet (CV) staining was used to determine cell growth over time. Cells were seeded onto wells and
allowed to attach. At the indicated time points, cells were fixed and then stained at the end of the experiment. The graph on the top shows the
mean relative CV absorbance every 24 h. Doubling time was calculated for control and USP19 silenced cell lines on the bottom (n ≥ 3, Kruskal–Wallis,
Dunn’s multiple comparison test. shRNA#1 p > 0.9999 and shRNA#2 p > 0.9999). The migratory potential was evaluated by two different experiments.
D Transwell assay: After 24 h of incubation, USP19-depleted cells were stained for microscopic examination and the number of migratory cells was
compared to control cells. The graph shows the number of migratory cells per transwell membrane (n= 4, one-way ANOVA, Dunnett’s multiple
comparison test. shRNA#1 p= 0.0187 and shRNA#2 p= 0.0001). EWound-healing assays: scratching with a pipette tip made a gap on a monolayer of
the different cell cultures, and time-lapse imaging monitored the number of migrating cells across the border. After 8 h, cells exhibited different levels
of migration. The graph on the left shows the gap covered area (mm2) after 8 h (n= 16, one-way ANOVA, Dunnett’s multiple comparison test.
shRNA#1 p < 0.0001 and shRNA#2 p < 0.0001) and the images on the right show representative areas in a wound-healing experiment at the indicated
time points. Scale bar= 100 μm.































































































Fig. 3 USP19 knockdown reduces cellular invasion. A Top left: Diagram of agar spot assay. MDAMB231 cells were seeded in wells (pink surface)
with drops of solidified agar (gray sphere) and allowed to invade along the bottom surface under the agar. Pictures were taken along the edge (the
edge is indicated by a dotted line); the displacement (d) is the extent of invasion under agar from the spot edge until the end of the experiment.
Bottom Left: Representative area showing cell invasion into an agar spot at the indicate time points. Top right: Quantification of the mean number of
invading cells per spot (n ≥ 4, one-way ANOVA, Dunnett’s multiple comparison test. shRNA#1 p= 0.0497 and shRNA#2 p= 0.0042) and bottom right:
cells mean displacement after 18 h (n ≥ 4, one-way ANOVA, Dunnett’s multiple comparison test. shRNA#1 p < 0.0001 and shRNA#2 p < 0.0001). Scale
bar= 100 μm. B Noble agar assay was used to study 3D culture proliferation and invasion. Left: Representative brightfield images obtained at
6 weeks in culture are shown. Scale bar= 150 μm. Right: Colony size was calculated at the end of the experiment (n= 2). C Left: Representative area
showing cell invasion in a Matrigel 3D experiment after 5 days in culture. Right: Colony area was calculated at the end of the experiment (n ≥ 3,
Kruskal–Wallis, Dunn’s multiple comparison test. shRNA#1 p= 0.1033 and shRNA#2 p= 0.0348). Scale bar= 150 μm.
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USP19 overexpression enhances migration and invasion
We then analyzed the effect of USP19 overexpression in
a poorly migratory and non-invasive breast cancer cell
line (MCF7).
For this purpose, we stably transfected MCF7 cells with a
USP19 overexpressing plasmid (Fig. 4A), and then per-
formed wound-healing assays. As shown in Fig. 4B, USP19
overexpression induced a significant increase in the gap
covered area, compared to the control cell line. As a control,
we overexpressed a catalytically mutant version of
USP1918,44–48 and a mutant lacking USP19 transmembrane
domain (Supp. Fig. 7). In contrast to USP19 wild type, we
did not detect any substantial increase in migration in either
of these mutants compared to the control cell line (Fig. 4B).
This result further supports the hypothesis that USP19
is a positive regulator of migration, and it provides evi-
dence that this phenotype is dependent on its catalytic
activity and on its subcellular localization.
Next, we analyzed the effect of USP19 overexpression
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Fig. 4 USP19 wild-type overexpression enhances migration and invasion in MCF7 cells. A Different constructs of USP19 were overexpressed in
MCF7 cells, and their expression confirmed by Western Blotting (n= 4, Kruskal–Wallis, Dunn’s multiple comparison test. WT p > 0.9999, C506S p=
0.0777, and WTΔTM p= 0.0070). B The migratory potential was evaluated by wound-healing assay. Left: gap covered area (mm2) after 12 h (n ≥ 4,
Kruskal–Wallis, Dunn’s multiple comparison test. WT p= 0.0107, C506S p > 0.9999, WTΔTM p > 0.9999) and right: representative areas in a wound-
healing experiment at the indicated time points. Scale bar= 100 μm. C Matrigel invasion was assessed over a 30 days period. Left: Representative
brightfield images obtained at the end of the experiment using a ×10 objective are shown; scale bar= 100 μm. Right: colony size was calculated
(n ≥ 4, Kruskal–Wallis, Dunn’s multiple comparison test. WT p= 0.0485, C506S p > 0.9999, WTΔTM p > 0.9999).
Rossi et al. Oncogenesis           (2021) 10:28 Page 8 of 15
Oncogenesis
matrix (Matrigel). We observed a significant increase in
colony areas when comparing wild-type USP19 over-
expressing cells to the control cell line (Fig. 4C). In
accordance with our previous results, the USP19-
dependent increase in invasion is also determined by its
catalytic activity and presence of the transmembrane
domain (Fig. 4C).
USP19 regulates invasion in vivo
To further characterize USP19-dependent control of
cell invasion in vivo, we first injected MDAMB231 control
or USP19-silenced cells subcutaneously in the mammary
fat pad of female mice. Tumor growth curves analysis
indicated that those generated from control cells were
significantly more volumetric than the ones originated
from USP19-silenced cells (Fig. 5A, left and Supp. Fig. 8).
Moreover, Kaplan–Meier curves for tumor-free survival
indicated that cells expressing either of the shRNAs tar-
geting USP19 generated fewer tumors (Fig. 5A, right and
Supp. Table 2). In addition, we observed similar results
using another breast cancer cell line (Supp. Fig. 9 and
Supp. Table 2).
Second, we analyzed USP19’s role in the regulation of
tumor cell lung colonization. For that purpose, we
inoculated control or USP19-silenced MDAMB231 cells
through tail vein injection and harvested the lungs two
months later. As shown in Fig. 5B, USP19 depletion
inhibits tumor foci formation in vivo, as evaluated by
human DNA quantification (left) and metastatic load
quantification in Hematoxylin & Eosin-stained lung sec-
tions (right, and Supp. Fig. 10). We observed the same
trend when another breast cancer cell line was used
(Supp. Fig. 9).
Last, we repeated the same type of tests using MCF7
cells in similar experimental conditions. We sub-
cutaneously injected control cells or cells expressing
either wild-type or catalytically mutant versions of USP19
in female mice.
In agreement with our in vitro experiments, wild-type
USP19-expressing cells formed tumors in all injected
mice, whereas mice injected with cells expressing the
catalytic mutant did not show signs of tumor growth
(Fig. 5C, Supp. Fig. 8 and Supp. Table 2). Since these
cell lines showed no difference in proliferation rates in
two dimensions (Supp. Fig. 11) and the fact that the
MCF7 cell line does not usually form tumors unless an
external estrogen source is supplied, this result high-
lights the importance of USP19 for tumor development
and onset.
Altogether, we concluded that USP19 is important for
in vivo colonization and tumor growth. In addition, our
results indicate that USP19 catalytic activity and trans-
membrane domain are required for its stimulatory effect
on cell motility.
USP19 regulates LRP6 protein levels in breast cancer cells
In order to study the putative mechanism of action
responsible for USP19 migration and invasion regulation,
we performed an in silico analysis on breast cancer mRNA
expression using publicly available datasets. Our results
revealed that high USP19 expression levels correlate with
the activation of the Wnt pathway (Fig. 6A, B, and C).
This result was in concordance with previous observa-
tions by Perrody and collaborators, which demonstrated
that USP19 stabilizes LRP6, a Wnt pathway coreceptor,
and that this interaction affected downstream Wnt
signaling22.
Based on these results, we analyzed LRP6 protein
steady-state levels upon USP19 genetic manipulation. In
accordance with Perrody et al., our results indicate that
LRP6 protein levels decrease upon USP19 silencing in
MDAMB231 (Fig. 6D) and increase in wild-type USP19-
overexpressing MCF7 cells, but not in cells expressing
catalytically dead or cytoplasmic mutant versions (Fig. 6E).
This correlation was also observed when using another
breast cancer cell line (Supp. Fig. 12).
In order to test the functional relation between USP19
and LRP6, we then analyzed the effect of LRP6 endo-
genous silencing in MCF7 cells overexpressing USP19.
Our results indicated that wild-type USP19-induced
increase in migration was reverted by LRP6 shRNAs
stable expression (Fig. 6F).
Altogether, our results indicate that the axis USP19/
LRP6, rather than the absolute level of expression of
USP19 (Supp. Fig. 12), is key to regulate the migratory
potential of breast cancer cells.
Survival analysis of USP19 expression in early breast
cancer patients
Finally, we analyzed USP19 protein expression in a
cohort study of early breast cancer patients with long-
term follow-up. Kaplan–Meier plots showed that over-
expression of USP19 was associated with a significantly
lower frequency of DRFS, while no significant correlation
with DFS was observed (Fig. 7A and B).
Multivariate analysis of DRFS, adjusted for other prog-
nostic factors, revealed that USP19High was an indepen-
dent prognostic predictor of DRFS (Supp. Table 3).
Altogether these findings indicate that USP19 repre-
sents a new predictor of distant metastasis formation in
early breast cancer patients.
Discussion
Migration occurs in a wide variety of physiological
conditions, and alterations in its regulation are associated
with different pathologies, including cancer3,4,49. In this
disease, mortality is associated primarily with tumor
growth at secondary sites, and effective therapies to block
the metastatic cascade are lacking5. In line with this
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reasoning, we chose to screen for genes that positively
regulate motility within the ubiquitination pathway, as
this cascade is currently emerging as an attractive ther-
apeutic target in drug development50–53. Here we report
the identification of USP19 as a positive regulator of
migration in breast cancer. USP19 was initially char-
acterized as a DUB predominantly localized in the cytosol















































































































































Fig. 5 Analysis of USP19 expression relevance using mice models. (A) Downregulation of USP19 attenuates tumorigenicity in vivo: Control or
USP19-silenced MDAMB231 cells were subcutaneously inoculated into the mammary fat pads of female NOD/SCID mice and tumor growth
monitored every 2–3 days. Left: tumor volume was calculated at the indicated time points (results show mean value ± S.E.); right: Kaplan–Meier
curves were built for tumor-free survival (TFS) over time (n ≥ 10, Log-Rank (Mantel-Cox) test, shRNA#1 p < 0.0001 and shRNA#2 p < 0.0001). B Silencing
effects of USP19 on experimental metastasis assays: NOD/SCID male mice were inoculated with MDAMB231 USP19-silenced cells through tail vein
injection and after 2 months, lungs were harvested. Top left: metastatic foci were estimated by qPCR human DNA quantification (n ≥ 6, Kruskal–Wallis,
Dunn’s multiple comparison test. shRNA#1 p= 0.9950 and shRNA#2 p= 0.0032). Bottom left: representative lung images stained with Indian ink at
the end of the experiment are shown. Scale bar= 1 cm. Right: metastatic load quantification was performed by evaluating lung Hematoxylin & Eosin-
stained slides. We used a lesion-based analysis of percent of metastatic pixels to compare the differences in metastatic load produced on the lungs
by the MDAMB231 cell lines (n= 6, Kruskal–Wallis, Dunn’s multiple comparison test. shRNA#1 p > 0.9999 and shRNA#2 p= 0.0299). C USP19 catalytic
activity is needed for tumorigenicity in vivo: control, WT or C506S mutant versions of USP19 overexpressing MCF7 cells were subcutaneously
inoculated into the mammary fat pads of female NOD/SCID mice. Left: tumor volume was calculated at the indicated time points (results show mean
value ± S.E.); right: Kaplan–Meier curves were built for tumor-free survival (TFS) over time (n ≥ 7, Log-Rank (Mantel-Cox) test, WT p < 0.0001, and C506S
p= 0.5307).
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has been associated with the regulation of the half-life of
several proteins that participate in different cellular pro-
cesses17,22,46,47,54–63.
Our in vitro validation experiments showed that USP19
depletion did not affect cell proliferation in agreement
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Fig. 6 (See legend on next page.)
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In addition, we observed that USP19 knockdown impaired
invasion (Figs. 2, 3, and Supp. Fig. 6) and also reduced
anchorage-independent growth (Fig. 3).
To further confirm our results, we analyzed how USP19
overexpression affected migration and invasion, using a
poorly migratory cell line. USP19 overexpression induced
an increase in cellular migration, invasion, and growth in
three-dimensional basement membrane cultures. These
effects were dependent on USP19 subcellular-localization,
and on the presence of a highly conserved cysteine at the
catalytic site (Fig. 4).
Our in vivo studies using immunocompromised mice
demonstrated that USP19 silencing decreased cell
engraftment and tumor growth, as well as colonization
into the lungs (Fig. 5A and Supp. Fig. 9B). On the con-
trary, overexpression of wild-type USP19, but not its
catalytically deficient mutant version, promoted tumor
growth (Fig. 5B). This is compatible with the requirement
of USP19 catalytic activity for local invasion and growth in
three dimensions, both in vitro and in vivo. In line with
these results, we observed a marked increase in USP19
mRNA expression in cells growing in tumors compared to
the same cells in culture dishes (Supp. Fig. 13). These
results are compatible with a requirement for higher levels
of USP19 to support three-dimensional invasion and
growth, highlighting the possible existence of a specific
regulation of USP19 in a context where cells need to
invade.
Finally, a retrospective study conducted on human
breast tumor samples indicated that high USP19 protein
levels are associated with a high-risk for metastatic relapse
in patients diagnosed with early breast cancer (Fig. 7).
Altogether these results provide evidence indicating
that USP19 has great potential as a therapeutic target for
drug development in breast cancer treatment.
To our knowledge, USP19 molecular mechanism of
action in the regulation of migration and invasion in
breast cancer cells was not investigated before.
Our results demonstrated that USP19 expression cor-
relates with tumor growth and invasion. Supporting this,
we analyzed E-cadherin protein expression levels in the
samples of our retrospective study and observed an
inverse correlation between USP19 and E-cadherin
expression (Supp. Table 4). In agreement with our
results, previous reports demonstrated that low E-
cadherin expression holds a prognostic value as a pre-
dictor of poorer prognosis and more aggressive pheno-
types in breast cancer65,66.
Moreover, we performed an in silico analysis on breast
cancer mRNA expression publicly available datasets,
which revealed that high USP19 expression levels corre-
late with the activation of the Wnt pathway (Fig. 6A, B
and C). This is consistent with a recent work that showed
that USP19 regulates LRP6 stability, a co-receptor of the
Wnt signaling cascade22. Particularly in breast cancer,
LRP6 is overexpressed in around a third of the patient
samples, and its overexpression has been proposed as a
distinctive feature of a specific class of breast cancer
subtype67.
In this regard, our experiments show that LRP6
expression positively correlates with USP19 protein levels
in breast cancer cells (Fig. 6D and E, and Supp. Fig. 12)
and that overexpression of a catalytically dead mutant or a
cytoplasmic version of USP19 has no effect on LRP6 (Fig.
6E), in concordance with the previous results22. More-
over, this molecular mechanism is specifically associated
with USP19 modulation and it is not a general effect as a
result of a change in migration, since downregulation of
USP10 and its concomitant reduction in migration does
not alter LRP6 protein levels (Supp. Fig. 5C). In all, our
results are compatible with former experiments that
demonstrated that LRP6 downregulation in breast cancer
cell lines reduces their migratory and invasive potential68,
as well as their ability to form colonies in soft agar67. More
importantly, we show that endogenous LRP6 silencing
abolishes USP19 overexpression-induced increase in
(see figure on previous page)
Fig. 6 USP19 mechanism of action. An in silico study was performed in order to analyze the relationship between USP19 expression levels and
different pathway activation status. A USP19 mRNA expression among primary breast carcinomas according to their intrinsic subtype. Expression
analysis showed a consistent upregulation in luminal A and B subtypes compared with basal-like and Her2 subtypes. B Luminal A/B primary breast
cancers divided into low (n= 77) or high (n= 209) USP19 mRNA expression levels. C Significantly activated pathways among Luminal A/B tumors
with high USP19 mRNA expression (n ≥ 77, SAM test, p < 0.01). Western blotting was performed in order to analyze LRP6 protein expression in breast
cancer cells upon USP19 genetic manipulation. D Top: Western blot quantification in control or USP19 silenced MDAMB231 cells (n= 6, one-way
ANOVA, Dunnett’s multiple comparison test. shRNA#1 p= 0.0416 and shRNA#2 p= 0.0102), bottom: representative image of a blot. E Top: Western
blot quantification in MCF7 cells overexpressing control or GFP-tagged USP19 constructs (n= 5, one-way ANOVA, Dunnett’s multiple comparison
test. WT p= 0.0484, C506S p= 0.8469 and WTΔTM p= 0.9968), bottom: representative image of a blot. F Wound-healing assays were performed in
order to analyze endogenous LRP6 silencing effects in MCF7 cells overexpressing WT or C506S mutant versions of USP19. Cells were stably
transduced with a control vector (‘ctrol’, PLKO.1 empty vector), or shRNAs targeting LRP6 (sh#1 and sh#2). Scratching with a pipette tip made a gap
on a monolayer of the different cell cultures, and time-lapse imaging monitored the number of migrating cells across the border. The graph shows
the gap covered area (mm2) after 8 h (n= 3, Kruskal–Wallis and Dunn’s multiple comparison test for WT or C506S overexpressing MCF7 cell lines,
analyzed separately. WT overexpressing MCF7 cell line: sh#1 p= 0.0341 and sh#2 p= 0.2021. C506S overexpressing MCF7 cell line: sh#1 p= 0.7422
and sh#2 p > 0.9999).
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migration (Fig. 6F). Consequently, our results indicate
that the functional interaction between USP19 and LRP6
is key for the regulatory effect that USP19 exerts on the
modulation of breast cancer cell migration and invasion.
Opposite to our findings, Hu and collaborators recently
demonstrated that USP19 negatively regulates prolifera-
tion and migration in clear cell renal carcinoma69. In this
type of cancer, the most relevant USP19 isoform is
uc003cvz.3, which is mainly localized in the cytoplasm70.
Based on our data showing that the control of cell
migration in breast cancer cells is mainly exerted by the
transmembrane USP19 isoform, it is plausible to assume
that this difference could contribute to explain the
divergent role that USP19 plays in these two different
cellular contexts.
For all the reasons expressed before, we conclude that
USP19 is relevant for the regulation of breast cancer cell
dissemination and its expression levels correlate with a
high risk of metastases development and could therefore
represent a novel target for the management of breast
cancer metastatic disease, in particular when LRP6
expression is relevant for determining patients’ outcome.
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